Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Multipotent mesenchymal stromal cells and rheumatoid arthritis: Risk or benefit?
Rheumatology, 07/01/09
Bouffi C et al. – Review discusses the new potential therapeutic applications of mesenchymal stromal cells (MSC)-based therapy in osteo-articular diseases, and also assesses the potential risks associated with it.
- MSCs play a dual role that may be of benefit in RA owing to their immunosuppressive properties and their potential of differentiation towards chondrocytes
- MSC-based cartilage engineering is a promising approach in case of cartilage injury
- It must be underlined that in case of chronic inflammation, the differentiation ability of MSCs is inhibited
- MSCs exert their immunosuppressive effect after activation by pro-inflammatory cytokines such as IFN-γ and IL-1β, secreted in arthritic joints
- Indeed, the local inflammation may be important for MSCs to display their therapeutic efficacy in RA
- An in vitro step of pre-conditioning of MSCs may also be required to more efficiently trigger the immunomodulatory potential of MSCs
- In conclusion, stromal cells appear as major regulatory cells in skeletal tissue homeostasis, controlling inflammation, immune response, fibrosis and tissue regeneration
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up
Scandinavian Journal of Rheumatology , 09/28/09
Sponsor
Article Search
Sponsor


See Latest Articles


